Drugmaker Regeneron Pharmaceuticals will buy the genetic testing firm through a bankruptcy auction
The drugmaker Regeneron Pharmaceuticals will buy the genetic testing firm 23andMe Holding for $256m through a bankruptcy auction, the companies said on Monday.
Regeneron said it will comply with 23andMe’s privacy policies and applicable laws with respect to the use of customer data and that it is ready to detail its intended use of the data to a court-appointed overseer. The companies expect to close the deal in the third quarter.
Drugmaker Regeneron Pharmaceuticals will buy the genetic testing firm through a bankruptcy auctionThe drugmaker Regeneron Pharmaceuticals will buy the genetic testing firm 23andMe Holding for $256m through a bankruptcy auction, the companies said on Monday.Regeneron said it will comply with 23andMe’s privacy policies and applicable laws with respect to the use of customer data and that it is ready to detail its intended use of the data to a court-appointed overseer. The companies expect to close the deal in the third quarter. Continue reading…
Discover more from Stay Updated Finance News
Subscribe to get the latest posts sent to your email.
